Literature DB >> 19997974

Proinflammatory and anti-inflammatory cytokines present in the acute phase of experimental colitis treated with Saccharomyces boulardii.

Nathália Nahas Grijó1, Ricardo Carneiro Borra, Vera Lucia Sdepanian.   

Abstract

PURPOSE: To study the proinflammatory and anti-inflammatory cytokines present in the acute phase of trinitrobenzene sulfonic acid (TNBS)-induced experimental colitis treated with Saccharomyces boulardii.
METHODS: Thirty male Wistar rats were divided into three groups: (1) treated group--received Saccharomyces boulardii for 14 days; (2) non-treated group--received sodium chloride solution for 14 days; (3) control group. Colitis was induced on the seventh day of the study in the treated and the non-treated groups using TNBS (10 mg) dissolved in 50% ethanol. Quantification of cytokines, including interleukin (IL)-1beta (IL-1beta), IL-6, transforming growth factor-beta (TGF-beta), IL-10 and tumor necrosis factor-alpha (TNF-alpha), in the serum and colonic tissue collected on day 14 were carried out using an enzyme-linked immunosorbent assay (ELISA).
RESULTS: The mean concentrations of TGF-beta in both the serum and the colonic tissue of the treated group were statistically higher than that of the control group. The mean concentration of TGF-beta in the colonic tissue of the non-treated group was also statistically higher than the control group.
CONCLUSION: The group treated with Saccharomyces boulardii showed increased amounts of TGF-beta, an anti-inflammatory cytokine, during the acute phase of colitis. There were no differences in the amount of TNF-alpha, IL-1beta, IL-6, and IL-10 between the treated and the non-treated or the control groups during the acute phase of experimental colitis induced by TNBS.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19997974     DOI: 10.1007/s10620-009-1072-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

Review 1.  Review article: How relevant to human inflammatory bowel disease are current animal models of intestinal inflammation?

Authors:  R B Sartor
Journal:  Aliment Pharmacol Ther       Date:  1997-12       Impact factor: 8.171

2.  Dietary fiber down-regulates colonic tumor necrosis factor alpha and nitric oxide production in trinitrobenzenesulfonic acid-induced colitic rats.

Authors:  Maria Elena Rodríguez-Cabezas; Julio Gálvez; Maria Dolores Lorente; Angel Concha; Desirée Camuesco; Shamira Azzouz; Antonio Osuna; Luis Redondo; Antonio Zarzuelo
Journal:  J Nutr       Date:  2002-11       Impact factor: 4.798

3.  Curcumin prevents and ameliorates trinitrobenzene sulfonic acid-induced colitis in mice.

Authors:  Ken Sugimoto; Hiroyuki Hanai; Kotaro Tozawa; Taiki Aoshi; Masato Uchijima; Toshi Nagata; Yukio Koide
Journal:  Gastroenterology       Date:  2002-12       Impact factor: 22.682

4.  Effects of Saccharomyces boulardii in children with acute diarrhoea.

Authors:  Z Kurugöl; G Koturoğlu
Journal:  Acta Paediatr       Date:  2005-01       Impact factor: 2.299

5.  The interrelated roles of TGF-beta and IL-10 in the regulation of experimental colitis.

Authors:  Ivan J Fuss; Monica Boirivant; Brian Lacy; Warren Strober
Journal:  J Immunol       Date:  2002-01-15       Impact factor: 5.422

6.  Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes.

Authors:  Guillaume Dalmasso; Françoise Cottrez; Véronique Imbert; Patricia Lagadec; Jean-François Peyron; Patrick Rampal; Dorota Czerucka; Hervé Groux; Arnaud Foussat; Valerie Brun
Journal:  Gastroenterology       Date:  2006-12       Impact factor: 22.682

7.  [Prevention of traveler's diarrhea with Saccharomyces boulardii. Results of a placebo controlled double-blind study].

Authors:  H Kollaritsch; H Holst; P Grobara; G Wiedermann
Journal:  Fortschr Med       Date:  1993-03-30

8.  A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease.

Authors:  L V McFarland; C M Surawicz; R N Greenberg; R Fekety; G W Elmer; K A Moyer; S A Melcher; K E Bowen; J L Cox; Z Noorani
Journal:  JAMA       Date:  1994 Jun 22-29       Impact factor: 56.272

9.  Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants.

Authors:  J P Buts; G Corthier; M Delmee
Journal:  J Pediatr Gastroenterol Nutr       Date:  1993-05       Impact factor: 2.839

10.  Numbers and strains of lactobacilli in some probiotic products.

Authors:  Valérie Coeuret; Micheline Gueguen; Jean Paul Vernoux
Journal:  Int J Food Microbiol       Date:  2004-12-15       Impact factor: 5.277

View more
  1 in total

1.  Gastrointestinal microbiota and some children diseases: a review.

Authors:  Thabata Koester Weber; Isabel Polanco
Journal:  Gastroenterol Res Pract       Date:  2012-10-30       Impact factor: 2.260

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.